Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Exosomes01:36

Overview of Exosomes

3.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.8K
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.0K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

Synergy Area With FDR-Controlled Evaluation (SAFE) to Robustly Assess Safety Profile in Clinical Trials.

Statistics in medicine·2026
Same author

Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH Alliance.

JACC. Cardiovascular interventions·2026
Same author

Editorial: The rapid rise of mechanical thrombectomy in pulmonary embolism: Innovation, diffusion, and the need for evidence.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Temporal Trends in Bleeding and Mortality in High-Risk Pulmonary Embolism: Findings From the PERT Consortium Database.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Mar 4, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.7K

Circulating Exosomal MicroRNAs as Potential Biomarkers for Pulmonary Embolism.

Chongyu Zhang1, Bulent Kantarcioglu1,2, Prakasha Kempaiah1

  • 1Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|March 3, 2026
PubMed
Summary

Researchers identified specific microRNAs (miRNAs) within small extracellular vesicles (sEVs) as potential biomarkers for diagnosing pulmonary embolism (PE) and predicting its severity. This novel approach offers improved diagnostic accuracy for PE.

Keywords:
Biomarker panelsExosomesExtracellular VesiclesPulmonary EmbolismSmall RNA SequencingmicroRNA

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
09:48

Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein

Published on: July 27, 2016

12.5K

Related Experiment Videos

Last Updated: Mar 4, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.3K
Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
09:48

Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein

Published on: July 27, 2016

12.5K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pulmonary Medicine

Background:

  • Pulmonary embolism (PE) diagnosis is challenging due to non-specific symptoms and limited diagnostic tools.
  • Plasma microRNAs (miRNAs) show some association with PE but lack diagnostic specificity.
  • Small extracellular vesicles (sEVs) play a role in PE pathogenesis, suggesting their cargo may hold diagnostic potential.

Purpose of the Study:

  • To investigate circulating microRNAs (miRNAs) within small extracellular vesicles (sEVs) as potential biomarkers for pulmonary embolism (PE).
  • To establish a feasible method for isolating sEVs and analyzing their miRNA content from small clinical plasma samples.
  • To explore the utility of sEV-derived miRNAs in diagnosing PE and predicting its severity.

Main Methods:

  • Developed a high-yield size-exclusion chromatography (SEC) method for isolating sEVs from plasma.
  • Utilized RNA sequencing (RNA-Seq) for unbiased analysis of sEV-derived miRNAs.
  • Analyzed pooled plasma samples from stratified PE patients (AHA criteria) and healthy controls.

Main Results:

  • PE patients exhibited larger sEVs compared to healthy individuals.
  • RNA-Seq revealed distinct miRNA expression patterns in sEVs associated with PE severity.
  • Differential miRNA expression was predicted to be involved in PE pathology-related processes.

Conclusions:

  • Circulating miRNAs within sEVs represent a promising avenue for PE biomarker discovery.
  • This approach can aid in PE diagnosis, severity prediction, and monitoring treatment response.
  • The strategy may be extendable to detecting adverse effects and drug-drug interactions.